LXRX – Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc.LXRX
$0.63Name : Lexicon Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $228,802,128.00
EPSttm : -0.63
Lexicon Pharmaceuticals, Inc.
$0.63
6.51%$0.0439Float Short %
20.66
Margin Of Safety %
Put/Call OI Ratio
0.11
EPS Next Q Diff
-0.01
EPS Last/This Y
0.2
EPS This/Next Y
0.07
Price
0.63
Target Price
2.95
Analyst Recom
2
Performance Q
-9.35
Relative Volume
0.3
Beta
1.05
Ticker: LXRX
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-04-14 | LXRX | 0.5361 | 0.08 | 0.01 | 47510 |
| 2025-04-15 | LXRX | 0.5119 | 0.08 | 1.32 | 48858 |
| 2025-04-16 | LXRX | 0.4995 | 0.08 | 1.06 | 48787 |
| 2025-04-17 | LXRX | 0.5097 | 0.09 | 0.02 | 49201 |
| 2025-04-18 | LXRX | 0.5098 | 0.09 | 0.02 | 49201 |
| 2025-04-21 | LXRX | 0.5705 | 0.10 | 0.03 | 23149 |
| 2025-04-22 | LXRX | 0.63 | 0.10 | 0.00 | 23618 |
| 2025-04-23 | LXRX | 0.6717 | 0.10 | 0.00 | 23687 |
| 2025-04-24 | LXRX | 0.7061 | 0.09 | 0.07 | 24405 |
| 2025-04-25 | LXRX | 0.7084 | 0.095399747573661 | 0.50989010989011 | 25169 |
| 2025-04-28 | LXRX | 0.688 | 0.1180937198473 | 0.020134228187919 | 26652 |
| 2025-04-29 | LXRX | 0.6723 | 0.11 | 0.26 | 27685 |
| 2025-04-30 | LXRX | 0.7231 | 0.12 | 0.02 | 27709 |
| 2025-05-01 | LXRX | 0.725 | 0.11 | 0.05 | 28036 |
| 2025-05-02 | LXRX | 0.6845 | 0.11 | 0.00 | 28115 |
| 2025-05-05 | LXRX | 0.72 | 0.11 | 0.01 | 29623 |
| 2025-05-06 | LXRX | 0.6686 | 0.11 | 0.02 | 29670 |
| 2025-05-07 | LXRX | 0.6766 | 0.11 | 0.06 | 29700 |
| 2025-05-08 | LXRX | 0.68 | 0.11 | 0.00 | 29880 |
| 2025-05-09 | LXRX | 0.689 | 0.11 | 0.05 | 29755 |
| 2025-05-12 | LXRX | 0.6756 | 0.11 | 0.01 | 29886 |
| 2025-05-13 | LXRX | 0.6508 | 0.11 | 0.06 | 30035 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-04-14 | LXRX | 0.53 | 48.3 | 48.6 | -0.43 |
| 2025-04-15 | LXRX | 0.51 | 48.3 | 76.7 | -0.43 |
| 2025-04-16 | LXRX | 0.50 | 48.3 | 74.3 | -0.43 |
| 2025-04-17 | LXRX | 0.51 | 48.3 | 56.2 | -0.43 |
| 2025-04-18 | LXRX | 0.51 | 48.3 | 63.5 | -0.43 |
| 2025-04-21 | LXRX | 0.57 | 48.3 | 15.2 | -0.43 |
| 2025-04-22 | LXRX | 0.64 | 48.3 | 29.9 | -0.43 |
| 2025-04-23 | LXRX | 0.67 | 48.3 | 50.6 | -0.43 |
| 2025-04-24 | LXRX | 0.71 | 48.3 | 52.9 | -0.43 |
| 2025-04-25 | LXRX | 0.71 | 48.3 | 62.3 | -0.43 |
| 2025-04-28 | LXRX | 0.69 | 48.3 | 70.8 | -0.43 |
| 2025-04-29 | LXRX | 0.67 | 48.3 | 71.4 | -0.43 |
| 2025-04-30 | LXRX | 0.73 | 48.3 | 40.6 | -0.43 |
| 2025-05-01 | LXRX | 0.72 | 48.3 | 63.4 | -0.43 |
| 2025-05-02 | LXRX | 0.68 | 48.3 | 78.1 | -0.43 |
| 2025-05-05 | LXRX | 0.72 | 48.3 | 49.1 | -0.43 |
| 2025-05-06 | LXRX | 0.66 | 48.3 | 84.6 | -0.43 |
| 2025-05-07 | LXRX | 0.69 | 48.3 | 52.0 | -0.43 |
| 2025-05-08 | LXRX | 0.68 | 48.3 | 64.8 | -0.43 |
| 2025-05-09 | LXRX | 0.69 | 48.3 | 61.7 | -0.43 |
| 2025-05-12 | LXRX | 0.67 | 48.3 | 73.5 | -0.43 |
| 2025-05-13 | LXRX | 0.63 | 48.3 | 81.0 | -0.43 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-04-14 | LXRX | 0.00 | 9.49 | 24.44 |
| 2025-04-15 | LXRX | 0.00 | 9.49 | 24.44 |
| 2025-04-16 | LXRX | 0.00 | 9.49 | 24.44 |
| 2025-04-17 | LXRX | 0.00 | 9.49 | 24.44 |
| 2025-04-18 | LXRX | 0.00 | 9.49 | 24.44 |
| 2025-04-21 | LXRX | 0.00 | 9.60 | 24.44 |
| 2025-04-22 | LXRX | 0.00 | 9.60 | 24.44 |
| 2025-04-23 | LXRX | 0.00 | 9.60 | 24.44 |
| 2025-04-24 | LXRX | 0.00 | 9.60 | 24.44 |
| 2025-04-25 | LXRX | 0.00 | 9.60 | 24.44 |
| 2025-04-28 | LXRX | 0.00 | 9.57 | 23.02 |
| 2025-04-29 | LXRX | 0.00 | 9.57 | 23.02 |
| 2025-04-30 | LXRX | 0.00 | 9.57 | 23.02 |
| 2025-05-01 | LXRX | 0.00 | 9.57 | 22.91 |
| 2025-05-02 | LXRX | 0.00 | 9.57 | 22.91 |
| 2025-05-05 | LXRX | 0.00 | 9.37 | 22.91 |
| 2025-05-06 | LXRX | 0.00 | 9.37 | 22.91 |
| 2025-05-07 | LXRX | 0.00 | 9.37 | 22.91 |
| 2025-05-08 | LXRX | 0.00 | 9.37 | 22.91 |
| 2025-05-09 | LXRX | 0.00 | 9.37 | 22.91 |
| 2025-05-12 | LXRX | 0.00 | 8.10 | 20.66 |
| 2025-05-13 | LXRX | 0.00 | 8.10 | 20.66 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.09
Avg. EPS Est. Current Quarter
-0.1
Avg. EPS Est. Next Quarter
-0.1
Insider Transactions
Institutional Transactions
8.1
Beta
1.05
Average Sales Estimate Current Quarter
1
Average Sales Estimate Next Quarter
1
Fair Value
Quality Score
37
Growth Score
48
Sentiment Score
4
Actual DrawDown %
93.5
Max Drawdown 5-Year %
-96.8
Target Price
2.95
P/E
Forward P/E
PEG
P/S
7.36
P/B
1.56
P/Free Cash Flow
EPS
-0.64
Average EPS Est. Cur. Y
-0.43
EPS Next Y. (Est.)
-0.36
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-644.78
Relative Volume
0.3
Return on Equity vs Sector %
-161
Return on Equity vs Industry %
-144
EPS 1 7Days Diff
-0.1
EPS 1 30Days Diff
0.07
EBIT Estimation
81
Lexicon Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 103
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company offers Sotagliflozin, an orally-delivered small molecule drug to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease or CKD, and other cardiovascular risk factors. Its orally-delivered small molecule drug candidates under development include sotagliflozin for the treatment of hypertrophic cardiomyopathy or HCM and type 1 diabetes that is in Phase 3 clinical trial; LX9211, which has completed Phase II clinical trials for the treatment of neuropathic pain; and LX9851 for the treatment of obesity and associated cardiometabolic disorders, as well as for weight management. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
stock quote shares LXRX – Lexicon Pharmaceuticals, Inc. Stock Price stock today
news today LXRX – Lexicon Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch LXRX – Lexicon Pharmaceuticals, Inc. yahoo finance google finance
stock history LXRX – Lexicon Pharmaceuticals, Inc. invest stock market
stock prices LXRX premarket after hours
ticker LXRX fair value insiders trading